This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. On June 9, 2025, Secretary of Health and Human Services Robert F. Kennedy Jr.
Other members include health-related associations and nonprofit organizations including the provider, research, and family caregiver communities; and businesses and organizations representing biopharmaceuticals, devices, diagnostics, generics, and payers.
Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. Topic sponsors are not involved in the creation of editorial content.
NHC 2025 Notice of Benefit and Payment Parameters (NBPP) Comments January 16, 2024 Allen Pinn, Coordinator, Policy The National Health Council (NHC) submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding the 2025 Notice of Benefit and Payment Parameters (NBPP) on January 8.
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!
Other members include health-related associations and nonprofit organizations including the provider, research, and family caregiver communities; and businesses and organizations representing biopharmaceuticals, devices, diagnostics, generics, and payers.
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Growing interest in SDoH aligns with the rising use of RWD, which offers valuable insights into diverse populations. For example, it’s important to consider whether someone has insurance (public or private), a job, and what their income may be.
Ensure Comprehensive Transparency in Formulary Management: Provide clear, comprehensive guidelines to Part D plans to ensure transparency in plan coverage, tiering, and utilization management (UM) policies, offering safeguards against practices that could restrict access to necessary treatments.
June 12, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Stargardt disease is a genetic retinal condition, resulting in progressive loss of vision and blindness. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!
However, we urge CMS to consider the following recommendations to ensure the 2025 policies further align with patient-centered care. The NHC recommends clear communication to beneficiaries about these changes and robust support systems to address any issues that may arise during the transition.
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. It is vital that communication, both for beneficiaries and for health care providers and pharmacists, adhere to these principles.
This is not a venue that patients and their advocates have access to, as health insurance plans are the primary users of the portal. CMS must ensure stakeholders have ample opportunity to provide input throughout the implementation and adjustment process. A simple 30-day comment period process will likely not be sufficient.
Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.
1 This trend underscores the importance of informed decision-making for those with chronic diseases and disabilities, who face crucial choices regarding their health care coverage – whether selecting between traditional Medicare and MA, choosing among MA plans, or navigating their selected plan to access necessary care. As of 2023, 30.8
June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The treatments can be accessed through facilities such as Royal Prince Alfred Hospital, Westmead Hospital and the Sydney Children’s Hospitals Network. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The alliance between the two entities will increase the production of new cancer therapies such as CAR T-cell treatment. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!
June 16, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Ethris’ platform technologies have shown favourable results in Phase I trials for ETH47. These platforms are designed for safe drug production while allowing scaleable manufacturing processes. Credit: Cryptographer/Shutterstock.
General Support for CMS Proposals The NHC commends CMS for its ongoing commitment to advancing health equity, improving access to care, ensuring program integrity, and maintaining affordability through Marketplace coverage. Copay Assistance and Drug Coverage in Large Group Plans Accumulator Adjustment Programs and Cost Sharing.
Robert Barrie June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!
16 We encourage CMS to continue refining these data collection processes to ensure they capture meaningful and actionable information. We believe this process is crucial for adapting the payment system to evolving clinical practices and emerging medical technologies.
Robert Barrie June 16, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Elevidys is the only gene therapy approved in US for DMD. The first death due to ALF, announced in March 2025, prompted the suspension of multiple clinical trials evaluating the gene therapy in different patient populations with DMD.
CY 2025 PFS proposed rule). The continuation of audio-only communication options remains essential. As these technologies become increasingly integral to patient care, it is essential for CMS to develop clear and consistent guidelines for the payment and coverage of AI-enabled services.
Robert Barrie June 17, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Eli Lilly has already secured several billion-dollar deals in 2025. Eli Lilly has already spent big in 2025. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Credit: JHVEPhoto via Shutterstock.
Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink.
3 Establishing a feedback loop with stakeholders during this monitoring process will provide additional safeguards against adverse effects. Engaging stakeholders in transparent decision-making processes is critical to the success of risk adjustment model updates.
Robert Barrie and Ross Law June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The removal ACIP members marks the most significant upheaval to the current vaccine landscape under Trump’s administration. lev radin via Shutterstock.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content